Compare iShares Gold Trust (IAU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Recursion Pharmaceuticals Inc — how do they compare? iShares Gold Trust trades at $76.83, while Recursion Pharmaceuticals Inc trades at $3.05 (market cap $1.53B). The key difference: iShares Gold Trust is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| IAU | RXRX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $6.79 |
52-Week Low | $61.62 | $2.84 |
Market Cap | — | $1.53B |
Enterprise Value | — | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU, the iShares Gold Trust ETF, trades at $75.35, down 0.2% on the day. Technical indicators are bearish, with moving averages signaling a downtrend and key support at $75. Recent news highlights institutional activity, including a new position by Eurizon Asset Management Hungary Ltd. in Q1 2026, while broader gold sentiment is pressured by expectations of sustained higher interest rates.
The outlook for IAU is influenced by macroeconomic factors affecting gold. Higher-for-longer interest rate expectations from the Fed (WSJ, 2026-07-19) pose a headwind, but structural central bank buying (WSJ, 2026-07-16) offers support. The primary risk is gold's sensitivity to monetary policy, while the opportunity lies in its role as a hedge amid economic uncertainty.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
